Journal
MOLECULAR NEUROBIOLOGY
Volume 47, Issue 2, Pages 587-597Publisher
SPRINGER
DOI: 10.1007/s12035-013-8394-x
Keywords
alpha-Synuclein; Parkinson's disease; Lewy bodies
Categories
Funding
- Wellcome Trust/MRC Joint Call in Neurodegeneration award [WT089698]
- Parkinson's UK
- Kattan Trust
- Medical Research Council [MC_G1000735] Funding Source: researchfish
- MRC [MC_G1000735] Funding Source: UKRI
Ask authors/readers for more resources
alpha-Synuclein (SNCA) is a substantive component of Lewy bodies, the pathological hallmark of Parkinson's disease (PD). The discovery and subsequent derivation of its role in PD has led to a suprising but fruitful convergence of the fields of biochemistry and molecular genetics. In particular, the manipulation of the cell lines of a number of forms of familial PD has implicated SNCA in distinct and diverse biochemical pathways related to its pathogenesis. This current and rapidly evolving concept indicates PD is a disease in which interacting pathways of oxidative stress, mitochondrial dysfunction and impaired regulation of protein turnover interact to cause dopaminergic cell dysfunction and death. SNCA has a central role in these processes and manipulation of its expression, degradation and aggregation appear to be promising neuroprotective therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available